These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25392091)

  • 1. Retraction: Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer.
    Xu L; Chi C; Wang C; Zhang LM
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):2982. PubMed ID: 25392091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer.
    Xu L; Chi C; Wang C; Zhang LM
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2687-92. PubMed ID: 25317804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
    Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
    Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aminolevulinic acid photodynamic therapy stimulates local immunity in patients with condylomata acuminata via activation of T lymphocytes.
    Du J; Cheng Q; Zhang Z; Wu JF; Li F; Chen SY; Wang YL; Lu XN; Xu JH
    Eur Rev Med Pharmacol Sci; 2017 May; 21(10):2302. PubMed ID: 28617562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
    Lereclus E; Tout M; Girault A; Baroukh N; Caulet M; Borg C; Bouché O; Ternant D; Paintaud G; Lecomte T; Raoul W
    BMC Cancer; 2017 Mar; 17(1):220. PubMed ID: 28347290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of VEGF on neuronal degeneration and interaction between Alzheimer's disease biomarkers.
    Yuan HC; Jiang CW; Hou LY; Lv YB; Feng XZ; Guo LF; Sun G; Liu K; Liu YJ; Xu B; Wang CY
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):3982. PubMed ID: 29028108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The study of endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms.
    Yu LL; Liu YJ; Wang ZH; Shi L; Liu LX
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1176. PubMed ID: 28387918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
    Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
    World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.
    Sibertin-Blanc C; Mancini J; Fabre A; Lagarde A; Del Grande J; Levy N; Seitz JF; Olschwang S; Dahan L
    Dig Liver Dis; 2015 Apr; 47(4):331-7. PubMed ID: 25617075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V; Hoff PM
    Oncology; 2010; 79(1-2):118-28. PubMed ID: 21088438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cytotoxicity of some common ophthalmic drugs.
    Li M; Chen XM; Liu JJ; Wang DM; Gan L; Lv X; Qiao Y
    Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3326. PubMed ID: 26439020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)].
    Oukkal M; Djilat K; Hadjam RM; Mahgoun M; Bentabak K; Graba A; Smail N; Kaci NA; Ahmed RB; Bouzid K
    Bull Cancer; 2010 Apr; 97(4):469-74. PubMed ID: 20385517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab.
    Hara M; Nagasaki T; Shiga K; Takahashi H; Takeyama H
    Surg Today; 2017 Apr; 47(4):483-489. PubMed ID: 27549777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate filament Nestin and the cell motility in cancer - a review.
    Shi AM; Tao ZQ; Wang X; Wang YQ
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3514. PubMed ID: 27649646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.